| David Bijan Bayne, MD | |
|
400 Parnassus Ave, San Francisco, CA 94143 | |
| (415) 353-2200 | |
| Not Available |
| Full Name | David Bijan Bayne |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 12 Years |
| Location | 400 Parnassus Ave, San Francisco, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215202627 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 129219 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ucsf Medical Center | San francisco, CA | Hospital |
| Zuckerberg San Francisco General Hosp & Trauma Ctr | San francisco, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ucsf Medical Group Business Services | 3779497870 | 1064 |
| University Of California Sfgh Medical Group | 5496668410 | 488 |
News Archive
As parents send their kids off for the first day of school, it's a good idea to put as much thought into what they're packing in their kids' lunchboxes as they do into their school supplies.
The southeastern US, including much of Texas through to Florida, have ideal conditions for spread of Zika virus according to a new study published in eLife.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
An interview with Simon Pickup from Liva Healthcare about the Liva digital health platform and how it is changing the lives of patients with chronic diseases.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
› Verified 6 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
As parents send their kids off for the first day of school, it's a good idea to put as much thought into what they're packing in their kids' lunchboxes as they do into their school supplies.
The southeastern US, including much of Texas through to Florida, have ideal conditions for spread of Zika virus according to a new study published in eLife.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
An interview with Simon Pickup from Liva Healthcare about the Liva digital health platform and how it is changing the lives of patients with chronic diseases.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
› Verified 6 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
As parents send their kids off for the first day of school, it's a good idea to put as much thought into what they're packing in their kids' lunchboxes as they do into their school supplies.
The southeastern US, including much of Texas through to Florida, have ideal conditions for spread of Zika virus according to a new study published in eLife.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
An interview with Simon Pickup from Liva Healthcare about the Liva digital health platform and how it is changing the lives of patients with chronic diseases.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
› Verified 6 days ago
| Entity Name | City & County Of San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982737524 PECOS PAC ID: 1658280748 Enrollment ID: O20050309000770 |
News Archive
As parents send their kids off for the first day of school, it's a good idea to put as much thought into what they're packing in their kids' lunchboxes as they do into their school supplies.
The southeastern US, including much of Texas through to Florida, have ideal conditions for spread of Zika virus according to a new study published in eLife.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
An interview with Simon Pickup from Liva Healthcare about the Liva digital health platform and how it is changing the lives of patients with chronic diseases.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
› Verified 6 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407821465 PECOS PAC ID: 5496668410 Enrollment ID: O20050328001098 |
News Archive
As parents send their kids off for the first day of school, it's a good idea to put as much thought into what they're packing in their kids' lunchboxes as they do into their school supplies.
The southeastern US, including much of Texas through to Florida, have ideal conditions for spread of Zika virus according to a new study published in eLife.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
An interview with Simon Pickup from Liva Healthcare about the Liva digital health platform and how it is changing the lives of patients with chronic diseases.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Bijan Bayne, MD 400 Parnassus Ave, San Francisco, CA 94143 Ph: () - | David Bijan Bayne, MD 400 Parnassus Ave, San Francisco, CA 94143 Ph: (415) 353-2200 |
News Archive
As parents send their kids off for the first day of school, it's a good idea to put as much thought into what they're packing in their kids' lunchboxes as they do into their school supplies.
The southeastern US, including much of Texas through to Florida, have ideal conditions for spread of Zika virus according to a new study published in eLife.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
An interview with Simon Pickup from Liva Healthcare about the Liva digital health platform and how it is changing the lives of patients with chronic diseases.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
› Verified 6 days ago
Dr. Wenwu Jin, M.D., PH.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 929 Clay St, Suite 505, San Francisco, CA 94108 Phone: 415-392-9690 Fax: 415-392-9695 | |
Raymond Fay, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 929 Clay St, #505, San Francisco, CA 94108 Phone: 415-392-9690 Fax: 415-392-9695 | |
Christi Butler, Urology Medicare: Accepting Medicare Assignments Practice Location: 400 Parnassus Avenue, 6th Floor, A610, San Francisco, CA 94143 Phone: 628-206-8000 | |
Mayra Lucas Ramirez, Urology Medicare: Not Enrolled in Medicare Practice Location: 400 Parnassus Ave # A633, San Francisco, CA 94143 Phone: 310-825-6373 | |
Dr. Antonio Otero, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 450 6th Ave, 4th Floor - Urology, San Francisco, CA 94118 Phone: 415-833-3239 Fax: 415-833-2563 | |
Dr. Kevin Shee, MD, PHD Urology Medicare: Medicare Enrolled Practice Location: 400 Parnassus Ave # A610, San Francisco, CA 94143 Phone: 415-885-3690 | |
Justin Ahn, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 400 Parnassus Ave, # A610, San Francisco, CA 94143 Phone: 415-885-7748 |